Initial experience with maribavir for the treatment of cytomegalovirus infection in kidney transplant recipients. (ERA 2026) - Apr 13, 2026 - Abstract #3160; Pres time: Jun 4, 2026; 10:00 AM - 11:00 AM; Location: Research Zone; "Nine patients received induction therapy with antilymphocyte antibodies, and eight received basiliximab...At the time of diagnosis, nine patients were receiving prophylaxis (eight with valganciclovir and one with letermovir), and eight were managed with a preemptive strategy...Conclusion Conclusion Maribavir is an effective and safe option for the treatment of CMV infection in kidney transplant recipients. Assessment of cellular immunity may help to identify early patients who may require individualized therapeutic strategies against CMV"
Clinical • Cytomegalovirus Infection • Hematological Disorders • Infectious Disease • Neutropenia • Transplantation
|
|
Gabriel Alberto Jiménez Colmenares1; Roberto Rangel Coronado1; Pablo González-Calero Borrás1; Jordi Espi Reig1; Ana Paz Ventura Galiano1; Maria Ramos Cebrian1; Diego Rodríguez Ortega1; María Peris Fernández1; Isabel Beneyto1; Pablo Molina1
|